CompaniesAnelixis Therapeutics

Anelixis Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (2)
View all

Total Trials

2

As Lead Sponsor

2

As Collaborator

0

Total Enrollment

54

By Phase

PHASE2: 2

By Status

WITHDRAWN: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
NCT04322149
NCT04711226
Hover over trial bars to see details

Recent Trials

NCT04711226Lead Sponsor
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
PHASE2Withdrawn
Started: Feb 19, 2021 · Completed: Jun 30, 2026
NCT04322149Lead Sponsor
Multiple Doses of AT-1501-A201 in Adults With ALS
PHASE2Completed
54 participants
Started: Oct 16, 2020 · Completed: Mar 24, 2022
Funding History (3)
D
May 17, 2019
Filing
D
Apr 25, 2018
Filing
D
Jun 20, 2017
Filing
Related Companies
Novus Therapeutics
acquired